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The Long-Term Oxygen Treatment Trial Research Group*

a bs t r ac t
BACKGROUND

Long-term treatment with supplemental oxygen has unknown efficacy in patients with
stable chronic obstructive pulmonary disease (COPD) and resting or exercise-induced
moderate desaturation.
METHODS

We originally designed the trial to test whether long-term treatment with supplemental
oxygen would result in a longer time to death than no use of supplemental oxygen among
patients who had stable COPD with moderate resting desaturation (oxyhemoglobin saturation as measured by pulse oximetry [Spo2], 89 to 93%). After 7 months and the randomization of 34 patients, the trial was redesigned to also include patients who had
stable COPD with moderate exercise-induced desaturation (during the 6-minute walk test,
Spo2 ≥80% for ≥5 minutes and <90% for ≥10 seconds) and to incorporate the time to the
first hospitalization for any cause into the new composite primary outcome. Patients were
randomly assigned, in a 1:1 ratio, to receive long-term supplemental oxygen (supplementaloxygen group) or no long-term supplemental oxygen (no-supplemental-oxygen group). In the
supplemental-oxygen group, patients with resting desaturation were prescribed 24-hour
oxygen, and those with desaturation only during exercise were prescribed oxygen during
exercise and sleep. The trial-group assignment was not masked.
RESULTS

A total of 738 patients at 42 centers were followed for 1 to 6 years. In a time-to-event
analysis, we found no significant difference between the supplemental-oxygen group and
the no-supplemental-oxygen group in the time to death or first hospitalization (hazard
ratio, 0.94; 95% confidence interval [CI], 0.79 to 1.12; P = 0.52), nor in the rates of all
hospitalizations (rate ratio, 1.01; 95% CI, 0.91 to 1.13), COPD exacerbations (rate ratio,
1.08; 95% CI, 0.98 to 1.19), and COPD-related hospitalizations (rate ratio, 0.99; 95% CI,
0.83 to 1.17). We found no consistent between-group differences in measures of quality
of life, lung function, and the distance walked in 6 minutes.
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CONCLUSIONS

In patients with stable COPD and resting or exercise-induced moderate desaturation, the
prescription of long-term supplemental oxygen did not result in a longer time to death or
first hospitalization than no long-term supplemental oxygen, nor did it provide sustained
benefit with regard to any of the other measured outcomes. (Funded by the National
Heart, Lung, and Blood Institute and the Centers for Medicare and Medicaid Services;
LOTT ClinicalTrials.gov number, NCT00692198.)
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wo trials that were conducted in
the 1970s showed that long-term treatment with supplemental oxygen reduced
mortality among patients with chronic obstructive pulmonary disease (COPD) and severe resting
hypoxemia.1,2 These results led to the recommendation that supplemental oxygen be administered to patients with an oxyhemoglobin saturation, as measured by pulse oximetry (Spo2), of less
than 89%.3,4 In the 1990s, two trials evaluated
long-term treatment with supplemental oxygen
in patients with COPD who had mild-to-moderate
daytime hypoxemia; neither trial showed a mortality benefit, but both were underpowered to
assess mortality.5,6 The effects of oxygen treatment on hospitalization,7-9 exercise performance,
and quality of life are unclear.10
Medicare reimbursements for oxygen-related
costs for patients with COPD exceeded $2 billion
in 2011.11 If long-term treatment with supplemental oxygen reduces the incidence of COPDrelated hospitalizations, increased use could be
cost-effective. Reliable estimates of the number
of prescriptions for supplemental oxygen that
are written for the indication of exercise-induced
desaturation are unavailable. Data suggest that
many patients with advanced emphysema who
are prescribed oxygen may not have severe resting hypoxemia.12
The Long-Term Oxygen Treatment Trial (LOTT)
was originally designed to test whether the use
of supplemental oxygen would result in a longer
time to death than no use of supplemental oxygen
among patients with COPD and moderate resting
desaturation (Spo2, 89 to 93%). After 7 months
and the randomization of 34 patients, the trial
design was judged to be infeasible owing to lowerthan-projected mortality and the phenotypic
overlap between patients with moderate resting
desaturation and those with exercise-induced desaturation. Accordingly, the investigators redesigned the trial to include patients with exerciseinduced desaturation and to incorporate the
secondary outcome of hospitalization for any
cause into the new composite primary outcome.
Patients who underwent randomization under the
original design continued in the redesigned trial.
The amended trial tested whether the use of
supplemental oxygen resulted in a longer time to
death or first hospitalization for any cause (composite primary outcome) than no use of supple-
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mental oxygen among patients with moderate
resting desaturation or moderate exercise-induced
desaturation. The original and amended trial
protocols are available with the full text of this
article at NEJM.org. Herein we report the primary and secondary outcomes and 11 of the 14
other outcomes listed in the trial protocol (see the
Supplementary Appendix, available at NEJM.org,
for the reasons that 3 outcomes are not reported).

Me thods
Design

We conducted this parallel-group, randomized
clinical trial of long-term supplemental oxygen
versus no long-term supplemental oxygen in
patients with COPD and moderate resting or
exercise-induced desaturation. Randomization
was performed in a 1:1 ratio, and the trial-group
assignment was not masked. The primary outcome in the time-to-event analysis, measured
from randomization, was the composite of death
or first hospitalization. The protocol specified
that the consistency of treatment effects would
be tested in subgroups of patients that were defined according to prespecified baseline characteristics. The protocol and amendments were
approved by the data and safety monitoring
board for the trial and by the institutional review board at each center. No materials were
donated to this trial.
Patients

A total of 14 regional clinical centers and their
associated sites (a total of 47 centers) screened
patients who had stable COPD and moderate
resting desaturation (Spo2, 89 to 93%) or moderate
exercise-induced desaturation (during the 6-minute walk test, Spo2 ≥80% for ≥5 minutes and
<90% for ≥10 seconds). All the patients signed
a contract in which they agreed not to smoke
while using oxygen, and they provided written
informed consent. Table S1 in the Supplementary Appendix lists all the selection criteria.
Interventions

Patients in the supplemental-oxygen group were
prescribed 24-hour oxygen if their resting Spo2
was 89 to 93% and oxygen only during sleep and
exercise if they had desaturation only during exercise. All the patients in the supplemental-oxygen
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group were prescribed stationary and portable scores indicating worse health-related quality
oxygen systems and 2 liters of oxygen per minute of life; minimum clinically important difference,
during sleep. Patients in the supplemental-oxygen 4).15,16 A total of 33 centers elected to obtain spigroup who had been prescribed 24-hour oxygen rometric measurements after randomization and
were prescribed 2 liters of oxygen per minute at to administer the Medical Outcomes Study 36-Item
rest. The ambulatory dose of oxygen was individu- Short-Form Health Survey (SF-36; the summary
ally prescribed and reassessed annually: 2 liters scores for the physical and mental components
of oxygen per minute or adjusted higher to main- each range from 0 to 100, with higher scores
tain an Spo2 of 90% or more for at least 2 minutes indicating better function; minimum clinically
while the patient was walking. The protocol important difference, 5),17 the Hospital Anxiety
specified that patients in the supplemental- and Depression Scale (scores on each measure
oxygen group continue the use of supplemental [anxiety or depression] range from 0 to 21, with
oxygen regardless of increase in the Spo2 level higher scores indicating greater anxiety or deand that patients in the no-supplemental-oxygen pression; minimum clinically important differgroup avoid the use of supplemental oxygen un- ence, 1.5),18,19 and the Pittsburgh Sleep Quality
less severe resting desaturation (Spo2 ≤88%) or Index (total scores range from 0 to 21, with
severe exercise-induced desaturation (Spo2 <80% higher scores indicating worse sleep quality).20
for ≥1 minute) developed. If either of these con- The protocol lists three additional outcomes
ditions developed, oxygen was prescribed and the (nutritional status, risk of cardiovascular disoxygen requirement was reassessed after 30 days. ease, and neurocognitive function) that are not
Each patient in the supplemental-oxygen group reported here.
spoke with an adherence educator regularly to
Patients attended visits yearly after randomdiscuss barriers to adherence to the assigned ization, were interviewed by telephone twice
regimen and to report average daily use. Each yearly, and completed mailed questionnaires at
patient in the group that received no long-term 4 months and 16 months (Table S2 in the Supsupplemental oxygen (no-supplemental-oxygen plementary Appendix). Details regarding the asgroup) spoke with an adherence educator 1 week certainment of the primary composite outcome
after randomization to discuss living without and procedures for measuring resting and exercisesupplemental oxygen. Every 4 months, all the induced desaturation are provided in the Supplepatients were asked about supplemental-oxygen mentary Appendix.
use; those who reported some oxygen use were
asked to estimate the average daily use. Patients Statistical Analysis
in the supplemental-oxygen group who used Calculation of the final required sample was
stationary oxygen concentrators also kept logs based on a time–to–composite event survival
of meter readings.
model with the use of the log-rank test statistic.
Assuming 90% power to detect a hazard ratio
Outcomes
for death or first hospitalization of 0.60 in the
In addition to the composite primary outcome supplemental-oxygen group versus the no-suppleand its components, outcomes included the inci- mental-oxygen group, a two-sided type I error
dence of COPD exacerbation, adherence to the rate of 0.05, an 11.7% overall crossover rate from
supplemental-oxygen regimen, development of the no-supplemental-oxygen group to the supplesevere resting desaturation (as assessed by means mental-oxygen group, and a 3.1% overall crossof pulse oximetry), development of severe exer- over rate from the supplemental-oxygen group
cise-induced desaturation (as assessed by means to the no-supplemental-oxygen group, we calcuof pulse oximetry), the distance walked in 6 min- lated a sample size of 737 patients. The hazard
utes, and scores on the Quality of Well-Being ratio of 0.60 corresponds to the smallest differScale (mean daily scores range from 0 to 1, with ence in mortality that the investigators judged to
higher scores indicating better quality of life; be clinically worthwhile (a 40% lower rate in the
minimum clinically important difference, 0.03)13,14 supplemental-oxygen group than in the no-suppleand the St. George’s Respiratory Questionnaire mental-oxygen group), on the basis of the number
(total scores range from 0 to 100, with higher of patients needed to treat. Because supplemen-
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tal oxygen is expensive and its use is burdensome,
the hazard ratio of 0.60 was also judged to be
appropriate for the composite primary outcome
of death or first hospitalization in the time-toevent analysis.
Under the original trial design, we assumed
that the crossover rate from the no-supplementaloxygen group to the supplemental-oxygen group
would be 21% and the crossover rate from the
supplemental-oxygen group to the no-supplemental-oxygen group would be 50%, on the basis
of investigator consensus. In March 2012, the
data and safety monitoring board approved the
use of the observed crossover rates of 11.7%
(from the no-supplemental-oxygen group to the
supplemental-oxygen group) and 3.1% (from the
supplemental-oxygen group to the no-supplemental-oxygen group) to refine the sample-size
calculation. Additional details about the samplesize calculation are provided in the Supplementary Appendix.
Data were analyzed according to the treatment
group to which the patients were randomly assigned (intention-to-treat approach) except as
otherwise noted. A Cox proportional-hazards
model21 with one binary covariate for treatment
group was used to estimate the between-group
hazard ratio for the primary composite outcome
in the time-to-event analysis; the log-rank test
was used for the P value. This method was also
used for each of the secondary outcomes in the
time-to-event analysis.
The consistency of the hazard ratio for the
primary outcome across prespecified subgroups
was assessed by a series of Cox proportionalhazard models with covariates that included the
treatment-group indicator, indicators for the
levels of the subgroup factor, and treatment-bysubgroup interaction terms. The P values for
consistency of hazard ratios across subgroups
were determined by Wald chi-square tests. Per the
trial protocol, all reported P values are nominal
and two-sided and were not corrected for multiple, prespecified comparisons. A P value of less
than 0.05 was considered to indicate statistical
significance for the composite primary outcome,
and a P value of less than 0.01 was considered to
indicate statistical significance for a treatmentby-subgroup interaction effect on the primary
outcome. Bonferroni corrections were used to
determine the P values that were required for
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statistical significance of the trial-group differences on the secondary and other outcomes and
for statistical significance of the multiple treatment-by-subgroup interaction effects on the primary outcome that were assessed.22 Additional
details about the statistical analysis are provided
in the protocol and the Supplementary Appendix.

R e sult s
Trial Population

From January 2009 through August 2014, a total
of 738 patients at 42 centers underwent randomization in the trial: 368 patients were randomly
assigned to the supplemental-oxygen group and
370 to the no-supplemental-oxygen group (Fig. S1
and Table S3 in the Supplementary Appendix). In
the supplemental-oxygen group, 220 patients were
prescribed 24-hour oxygen and 148 were prescribed oxygen during exercise and sleep only.
Of the 738 patients who underwent randomization, 133 (18%) had resting desaturation only, 319
(43%) had exercise-induced desaturation only,
and 286 (39%) had both types of desaturation.
The trial groups were similar at baseline except
that the patients in the supplemental-oxygen
group had a lower BODE index (a scoring system
incorporating information on the body-mass index, airflow obstruction, dyspnea, and 6-minute
walk distance; higher scores indicate a greater
risk of death)23 than those in the no-supplemental-oxygen group (Table 1, and Table S4 in the
Supplementary Appendix).
Patients were followed for 1 to 6 years; the
last visits occurred during the period from May
through August 2015 (median follow-up, 18.4
months). Vital status as of August 31, 2015, was
ascertained in all patients. A total of 97% of the
patients had at least 1 year of follow-up for hospitalization. Most patients in the supplementaloxygen group used 2 liters of oxygen per minute
during exercise throughout follow-up (Table S5
in the Supplementary Appendix).
Primary Outcome

In a time-to-event analysis, we found no significant difference between the trial groups in the
composite outcome of death or first hospitalization for any cause or in either component (Fig. 1
and Table 2). No significant difference was noted in the subgroups defined according to oxygen
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Table 1. Characteristics of the Patients at Enrollment.*
No Supplemental
Oxygen
(N = 370)

Supplemental
Oxygen
(N = 368)

Age — yr

69.3±7.4

68.3±7.5

Male sex — no. (%)

276 (75)

266 (72)

Characteristic

Race — no. (%)†
Black

34 (9)

46 (12)

White

328 (89)

311 (85)

Other

11 (3)

17 (5)

273 (74)

268 (73)

Current tobacco-cigarette smoker — no. (%)

92 (25)

110 (30)

Quality of Well-Being Scale mean daily score‡

0.56±0.13

0.56±0.13

St. George’s Respiratory Questionnaire total score§

50.2±17.1

49.8±18.7

Medicare coverage — no. (%)

Oxygen-desaturation type qualifying the patient for enrollment
— no. (%)
Resting only

60 (16)

73 (20)

Exercise only

171 (46)

148 (40)

Resting and exercise

139 (38)

147 (40)

All patients

93.5±1.9

93.3±2.1

Resting only

92.3±0.8

92.4±0.9

Exercise only

95.2±1.2

95.4±1.4

Resting and exercise

91.9±1.2

91.7±1.1

Spo2 at rest while breathing ambient air — %

Nadir Spo2 during 6-min walk while breathing ambient air
— no./total no. (%)¶
<86%

85/290 (29)

86/292 (29)

86–88%

103/290 (36)

105/292 (36)

>88%

102/290 (35)

101/292 (35)

*	Plus-minus values are means ±SD. There were no significant differences at baseline between the group of patients
assigned to receive long-term supplemental oxygen (supplemental-oxygen group) and the group of those assigned to
receive no long-term supplemental oxygen (no-supplemental-oxygen group), except that the patients in the supplementaloxygen group had a lower BODE index (a scoring system incorporating information on body-mass index, airflow obstruction, dyspnea, and 6-minute walk distance; higher scores indicate a greater risk of death)23 than those in the no-supplemental-oxygen group (P = 0.007); details of the BODE index values and other characteristics at baseline are provided
in Table S4 in the Supplementary Appendix. Spo2 denotes oxyhemoglobin saturation as measured by means of pulse
oximetry.
†	Race was self-reported. Patients were permitted to select more than one race group.
‡	The Quality of Well-Being Scale is a 77-item quality-of-life questionnaire completed by the patient. A score of 0 indicates
death. The mean daily score ranges from 0 to 1, with higher scores indicating better quality of life. The minimum clinically important difference is 0.03.13,14
§	The St. George’s Respiratory Questionnaire is a 51-item questionnaire on the health-related quality of life with regard to
respiratory symptoms that is completed by the patient. The total score ranges from 0 to 100, with lower scores indicating better health-related qualify of life. The minimum clinically important difference is 4.15,16
¶	The nadir Spo2 is the 10th lowest Spo2 observed during the 6-minute walk. A total of 10 patients (6 patients in the supplemental-oxygen group and 4 in the no-supplemental-oxygen group) either did not attempt or began but did not complete the 6-minute walk. Reasons included being in a wheelchair, amputation of foot or leg, sciatic pain, starting the walk
and stopping because of back pain, or other reason; these 10 participants met the resting hypoxemia criterion. The
nadir Spo2 could not be calculated for 146 patients (70 patients in the supplemental-oxygen group and 76 in the nosupplemental-oxygen group) owing to loss of their oximetry data file or a technical issue with their oximetry data file
obtained at enrollment.
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A Primary Outcome (Death or First Hospitalization) or First Hospitalization
1.0

Supplemental oxygen, primary outcome
Supplemental oxygen, first hospitalization

0.9

No supplemental oxygen, primary outcome
No supplemental oxygen, first hospitalization

Cumulative Probability

0.8
0.7
0.6
0.5
0.4
0.3
0.2

Death or first hospitalization, P=0.52 by log-rank test
First hospitalization, P=0.37 by log-rank test

0.1
0.0

0
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18

24
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36

42

48

54
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24
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13

7
6

1
1

Months since Randomization
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No supplemental oxygen
Supplemental oxygen
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243
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125

76
86

59
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43
44

B Death
1.0
0.9
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0.8
0.7
0.6
0.5
0.4
0.3

No supplemental oxygen

0.2

Supplemental oxygen

0.1
0.0

P=0.53 by log-rank test
0
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36
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116
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No supplemental oxygen
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370
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366
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294

242
245

210
216

177
184

152
149

Figure 1. Kaplan–Meier Analyses of the Primary Outcome of Death or First Hospitalization for Any Cause
and for the Component Events in the Intention-to-Treat Population.
Panel A shows the results of a time-to-event analysis of the primary outcome, which was a composite of death or first
hospitalization for any cause; the median follow-up was 18.4 months. Data for 120 patients who were assigned to receive long-term supplemental oxygen (supplemental-oxygen group) and 120 assigned to receive no long-term supplemental oxygen (no-supplemental-oxygen group) who neither died nor had a hospitalization were censored at the date
of the last interview. Error bars indicate 95% confidence intervals (assessed every 12 months). For the time-to-event
analysis of the first hospitalization for any cause, the median follow-up was 18.4 months. Data for 139 patients in the
supplemental-oxygen group and 133 in the no-supplemental-oxygen group were censored as of their date of death (if
there was no hospitalization before death) or as of the date of their last interview (if they were alive and had no hospitalization). Panel B shows the results of a time-to-event analysis of death; the median follow-up was 41.5 months.
Data for 302 patients in the supplemental-oxygen group and 297 in the no-supplemental-oxygen group who were alive
on August 31, 2015, were censored as of that date. The hazard ratios and 95% confidence limits were derived from
Cox regression models, with supplemental oxygen versus no supplemental oxygen as the single model variable. P values were derived from log-rank tests. For the components of the composite primary outcome (death and first hospitalization), a P value of less than 0.025 (0.05 divided by 2) was considered to indicate statistical significance, with the
use of a Bonferroni adjustment for multiple comparisons.22
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Table 2. Primary Composite Outcome of Death or First Hospitalization for Any Cause and Composite Events
in the Intention-to-Treat Population.*
No Supplemental
Oxygen
(N = 370)

Outcome

Supplemental
Oxygen
(N = 368)

Hazard Ratio
(95% CI)

P Value

0.94 (0.79–1.12)

0.52

0.90 (0.64–1.25)

0.53

0.92 (0.77–1.10)

0.37

Primary outcome
Death or first hospitalization for any cause
No. of events

250

248

Composite rate per 100 person-yr

36.4

34.2

Primary-outcome component events
Death
No. of deaths

73

66

Rate per 100 person-yr

5.7

5.2

First hospitalization for any cause
No. of first hospitalizations

237

229

Rate per 100 person-yr

34.5

31.6

*	The primary outcome was death or first hospitalization for any cause, whichever came first, in patients randomly assigned to receive supplemental oxygen as compared with those assigned to receive no supplemental oxygen. For the
composite-event analysis, data from 120 patients in the supplemental-oxygen group and 120 in the no-supplementaloxygen group who neither died nor had a hospitalization were censored as of their last interview. For the analysis of
death, data for 302 patients in the supplemental-oxygen group and 297 in the no-supplemental-oxygen group who were
alive on August 31, 2015, were censored as of that date. For the analysis of the first hospitalization, data for 139 patients
in the supplemental-oxygen group and 133 in the no-supplemental-oxygen group were censored as of their date of death
(if there was no hospitalization before death) or as of the date of their last interview (if they were alive and had no hospitalization). For the components of the composite primary outcome (death and first hospitalization), a P value of less
than 0.025 (0.05 divided by 2) was considered to indicate statistical significance, with the use of a Bonferroni adjustment for multiplicity of comparisons.22 P values were calculated by the log-rank test. CI denotes confidence interval.

prescription, desaturation profile, race, sex,
smoking status, nadir Spo2 during exercise (the
10th lowest Spo2 observed during the 6-minute
walk), forced expiratory volume in 1 second,
BODE index, SF-36 physical-component score,
body-mass index, or history of anemia (Table S6
in the Supplementary Appendix).
Patients in the supplemental-oxygen group
who reported having had a COPD exacerbation
1 to 3 months before enrollment had a longer
time to death or first hospitalization than similar patients in the no-supplemental-oxygen group
(hazard ratio, 0.58; 95% confidence interval [CI],
0.39 to 0.88; P = 0.007 for interaction), as did
patients who were 71 years of age or older at
enrollment (hazard ratio, 0.75; 95% CI, 0.57 to
0.99; P = 0.03 for interaction) and those who had
a lower quality of life (Quality of Well-Being
Scale score, <0.55) at enrollment (hazard ratio,
0.77; 95% CI, 0.60 to 0.99; P = 0.03 for interaction). However, none of these subgroup-bytreatment interaction effects were significant
when the analysis was adjusted for multiple
n engl j med 375;17

comparisons. In the as-treated analysis, no difference was found between patients who used
oxygen for at least 16 hours per day and all
others. (Details are provided in Tables S6 and
S7 in the Supplementary Appendix.)
Adherence to Regimen

Histograms of self-reported use of supplemental
oxygen as averaged over follow-up indicate much
longer daily mean (±SD) use in the supplementaloxygen group than in the no-supplemental-oxygen
group (13.6±6.1 vs. 1.8±3.9 hours per day) (Fig. 2).
There was a separation of patients in the supplemental-oxygen group according to prescription
(15.1±6.2 hours per day in the 24-hour group vs.
11.3±5.0 hours per day in the sleep–exercise
group), but there was considerable overlap. A comparison of self-reported stationary concentrator
use with use that was calculated from meter
readings in 100 patients in the supplementaloxygen group who had available data showed a
significant linear trend in bias (P<0.001), in
which patients with less-than-average hours of
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Figure 2. Self-Reported Use of Supplemental Oxygen during Follow-up.
Shown are histograms of total self-reported hours of supplemental-oxygen use per day (sum of stationary use and
portable use) according to randomized assignment and prescription for supplemental oxygen (24-hour use or use
during sleep and exercise). Plus–minus values are means ±SD. The value plotted for a patient is the mean of all the
patient’s self-reports during follow-up. Self-reports were obtained 3 times yearly in the no-supplemental-oxygen
group. In the supplemental-oxygen group, self-reports were more frequent during year 1 (12 times) and were obtained 3 times yearly thereafter. The median number of self-reports for a patient was 20 in the supplemental-oxygen
group (range, 6 to 20) and 8 in the no-supplemental-oxygen group (range, 0 to 18). All the patients in the supplemental-oxygen group provided at least one assessment; 363 patients (98%) in the no-supplemental-oxygen group
provided at least one assessment. IQR denotes interquartile range.

daily use tended to overestimate their use and
those with greater-than-average hours of daily
use tended to underestimate their use (Fig. S2 in
the Supplementary Appendix).
Comparison with Design Assumptions

Fewer enrollees than expected were hospitalized
in the year before screening. However, more
patients than expected were hospitalized during
follow-up. Observed mortality rates compared
well with the design assumptions (Table S8 in
the Supplementary Appendix).
1624
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Other Outcomes

The two trial groups did not differ significantly
with regard to the rates of all hospitalizations
(rate ratio, 1.01; 95% CI, 0.91 to 1.13), COPD
exacerbations (rate ratio, 1.08; 95% CI, 0.98 to
1.19), COPD-related hospitalizations (rate ratio,
0.99; 95% CI, 0.83 to 1.17), or non–COPD-related
hospitalizations (rate ratio, 1.03; 95% CI, 0.90 to
1.18). (Fig. S3 and Table S9 in the Supplementary Appendix). We found no consistent differences between groups in the change from baseline in measures of quality of life, anxiety,

nejm.org

October 27, 2016

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on November 15, 2016. For personal use only. No other uses without permission.
Copyright © 2016 Massachusetts Medical Society. All rights reserved.

Long-Term Oxygen for COPD with Moder ate Desatur ation

depression, or in lung function, distance walked
A systematic review and meta-analysis sugin 6 minutes, or other measures of functional gested that oxygen therapy may reduce dyspnea
status (Fig. S4 and Table S10 in the Supplemen- in patients with COPD and mild or no hypoxtary Appendix).
emia.27 We found no consistent benefit of longterm supplemental oxygen with regard to meaAdverse Events
sures of quality of life, depression, anxiety, or
A total of 51 adverse events were attributed to functional status.
the use of supplemental oxygen (Table S11 in the
This trial has some limitations. First, some
Supplementary Appendix). There were 23 reports patients may not have enrolled in the trial beof tripping over equipment, with two patients cause they or their providers believed that they
requiring hospitalization. Five patients reported were too ill or that they benefited from oxygen.
a total of six instances of fires or burns, with Highly symptomatic patients who declined enone patient requiring hospitalization.
rollment might have had a different response to
oxygen than what we observed in the enrolled
patients. Second, the lack of masking may have
Discussion
influenced some of the patient-reported outWe found that the prescription of supplemental comes; however, it is unlikely to have influenced
oxygen for patients with stable COPD and rest- the primary outcome. Third, we did not use uniing or exercise-induced moderate desaturation form devices for oxygen delivery; it is possible
did not affect the time to death or first hospital- that there was variability in the amount of oxyization, time to death, time to first hospitaliza- gen delivered. Fourth, the immediate effects of
tion, time to first COPD exacerbation, time to oxygen on symptoms or exercise performance
first hospitalization for a COPD exacerbation, were not assessed. We did not measure nocturthe rate of all hospitalizations, the rate of all nal oxygen saturation; some patients with COPD
COPD exacerbations, or changes in measures of and severe nocturnal desaturation might benefit
quality of life, depression, anxiety, or functional from nocturnal oxygen supplementation.28,29 Fifth,
status. We found no effect on the primary out- patients’ self-reported adherence may have been
come in subgroups of patients defined according an overestimate of their actual oxygen use. Howto desaturation type, prescription type, or adher- ever, we found good agreement with the use as
ence to the regimen. The consistency of the null measured by means of serial meter readings on
findings strengthens the overall conclusion that the concentrator. The estimated mean hours per
long-term supplemental oxygen in patients with day of use in the supplemental-oxygen group
stable COPD and resting or exercise-induced (15.1±6.2 hours per day in the 24-hour group
moderate desaturation has no benefit with regard and 11.3±5.0 hours per day in the sleep–exercise
to the multiple outcomes measured.
group) (Fig. 2) was similar to the use observed
Our data support the conclusions of earlier in the Nocturnal Oxygen Therapy Trial (17.7 hours
studies that among patients with COPD who per day in the continuous-oxygen group and
have a resting Spo2 of more than 88%, long-term 12.0 hours per day in the nocturnal-oxygen
treatment with supplemental oxygen does not re- group).1 However, we cannot exclude the possult in longer survival than no long-term supple- sibility that longer exposures to oxygen in the
mental oxygen therapy, regardless of whether supplemental-oxygen group might have given
the patients have exercise-induced desaturation.5,6,24 different results. Finally, because hospitalization
Our findings contrast with the prolonged survival was recorded from self-report every 4 months,
that was observed among patients with COPD it is possible that we underestimated the numand severe desaturation who were treated with ber of hospitalizations; however, there did not
supplemental oxygen.1,2 Possible reasons for this appear to be systematic bias in follow-up bediscrepancy are the nonlinear threshold effects tween groups.
of oxygen saturation on pulmonary vasoconstricIn conclusion, among patients with stable
tion, mediator release, and ventilatory drive,25,26 COPD and resting or exercise-induced moderate
which occur with an Spo2 of 88% or less and desaturation, we found that long-term supplewhich may be more important in patients with mental oxygen did not provide any benefit with
chronic hypoxemia.
respect to the time to death or first hospitalizan engl j med 375;17
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